Psychoactive drugs alter brain function and behavior by modifying synaptic neurotransmission. Agonists activate receptors (increasing neural activity); antagonists block them (decreasing activity). Drugs vary in selectivity for neurotransmitter systems (SSRIs selectively increase serotonin by blocking reuptake; stimulants block monoamine reuptake or increase release). Understanding mechanism-of-action is essential for predicting behavioral effects, side effects, drug interactions, and individual differences in drug response. Tolerance develops through receptor downregulation and other adaptive mechanisms.
Study dose-response curves showing affinity and efficacy. Compare drugs within classes (different SSRIs) and across classes (SSRIs vs. tricyclics). Examine human pharmacology studies showing brain penetration, receptor occupancy, and behavioral effects. Study tolerance and dependence mechanisms.
One drug produces one effect / tolerance doesn't involve receptor changes / side effects are independent of mechanism / all drugs work on the brain the same way.
You already understand how neurotransmitters bind to receptors and how second messenger cascades amplify those signals intracellularly. Psychopharmacology builds directly on this foundation: psychoactive drugs are molecules that enter the brain and modify synaptic neurotransmission, typically by mimicking, enhancing, or blocking the endogenous molecules you studied. Understanding a drug's mechanism of action is what connects its chemistry to its behavioral effects — and what distinguishes rational pharmacology from trial-and-error.
The most fundamental distinction is between agonists and antagonists. An agonist activates a receptor, mimicking or augmenting the effect of the natural neurotransmitter. An antagonist binds to the receptor without activating it, blocking the natural transmitter from gaining access. Morphine is an opioid receptor agonist — it activates the same receptors that endogenous endorphins activate, producing analgesia and euphoria. Naloxone is an opioid antagonist — it occupies those same receptors without activating them, reversing overdose within minutes. The same receptor population, operated in completely opposite directions, produces opposite behavioral outcomes. This is why knowing which receptor a drug acts on is insufficient: you must also know whether it activates or blocks.
Beyond direct receptor binding, drugs can work by altering neurotransmitter availability at the synapse. SSRIs (selective serotonin reuptake inhibitors) do not directly activate serotonin receptors. Instead, they block the reuptake transporter that normally clears serotonin from the synapse after release. The result is that serotonin remains active longer, producing greater cumulative receptor stimulation — even though the drug never touches the receptor itself. This mechanism selectivity matters clinically: an SSRI and a direct serotonin agonist might both increase serotonergic signaling, but they differ in receptor specificity, temporal dynamics, and side effect profiles. Understanding the mechanism predicts these differences.
Tolerance illustrates how the brain uses the same intracellular machinery you studied to adapt to sustained drug exposure. When a receptor is persistently activated by an agonist, the cell reduces its responsiveness through receptor downregulation — literally reducing the number of functional surface receptors or decreasing their sensitivity via second-messenger feedback. This cellular adaptation is the basis of tolerance: more drug is required to produce the same effect because the receptor population has shrunk. Dependence and withdrawal follow logically: when the drug is removed from a system that has downregulated its receptors, the system is now under-responsive to its own neurotransmitters until the receptors recover. Withdrawal symptoms are essentially the mirror image of the drug's original effects.
The key principle uniting all of this is mechanism selectivity. Every drug has a profile of targets — receptors, transporters, enzymes — it affects, and that profile explains its therapeutic effects, its side effects, and its potential for abuse. The more selective a drug is for a single target, the cleaner its behavioral profile, but also the more limited its reach. This is why understanding mechanism-of-action is not merely academic: it predicts drug interactions, tolerance timelines, why patients with different receptor genetics respond differently to the same dose, and why moving a patient from one drug class to another requires careful management of adaptive states the brain has already built up.